HC Deb 15 December 1983 vol 50 c566W
Mr. Murphy

asked the Secretary of State for Social Services if the revised National Health Service pharmaceutical price regulation scheme will contain safeguards to ensure adequate investment in new drug development.

Mr. Kenneth Clarke

A company's expenditure on research and development will continue to be accepted. within reasonable limits, as a legitimate cost in the pricing of NHS medicines and will influence its approved profit target under the Pharmaceutical Price Regulation Scheme.